RXi Pharmaceuticals (RXII) Strengthens NeuVax(TM) (E75) Patent Portfolio
7/13/2011 7:34:08 AM
WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced today that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax™ (E75). The patents licensed from The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) cover the use of NeuVax in combination with trastuzumab (Herceptin®; Genentech/Roche), and use in low-to-intermediate HER2+ (Human Epidermal growth factor Receptor) breast cancer patients not eligible for Herceptin therapy. These patents are added to the growing family of patents for RXi to support the development of NeuVax in a variety of indications and countries. NeuVax was discovered at The M. D. Anderson Cancer Center (MDACC) and licensed from MDACC and HJF.